Optomed Oyj Valuation
Is 36U0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 36U0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 36U0 (€3.92) is trading below our estimate of fair value (€27.08)
Significantly Below Fair Value: 36U0 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 36U0?
Key metric: As 36U0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 36U0's PS Ratio? | |
|---|---|
| PS Ratio | 5.8x |
| Sales | €13.60m |
| Market Cap | €78.38m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.2x |
| Enterprise Value/EBITDA | -14.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 36U0's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
PUS PULSION Medical Systems | 3.8x | n/a | €134.4m |
AAQ1 aap Implantate | 1.9x | n/a | €22.4m |
SBS Stratec | 1.3x | 7.7% | €334.9m |
GME Geratherm Medical | 1x | 1.9% | €21.0m |
36U0 Optomed Oyj | 5.8x | 29.8% | €78.4m |
Price-To-Sales vs Peers: 36U0 is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does 36U0's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: 36U0 is expensive based on its Price-To-Sales Ratio (5.8x) compared to the European Medical Equipment industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is 36U0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.8x |
| Fair PS Ratio | 3.3x |
Price-To-Sales vs Fair Ratio: 36U0 is expensive based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €3.92 | €5.83 +49.0% | 14.6% | €7.00 | €5.00 | n/a | 3 |
| Nov ’25 | €3.72 | €6.37 +71.4% | 13.2% | €7.50 | €5.50 | n/a | 3 |
| Oct ’25 | €4.71 | €6.37 +35.3% | 13.2% | €7.50 | €5.50 | n/a | 3 |
| Sep ’25 | €5.18 | €6.43 +24.2% | 12.0% | €7.50 | €5.70 | n/a | 3 |
| Aug ’25 | €6.02 | €6.20 +3.0% | 6.5% | €6.60 | €5.80 | n/a | 2 |
| Jul ’25 | €6.19 | €6.20 +0.2% | 6.5% | €6.60 | €5.80 | n/a | 2 |
| Jun ’25 | €6.50 | €6.63 +2.1% | 14.7% | €8.00 | €5.80 | n/a | 3 |
| May ’25 | €4.33 | €5.80 +33.9% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Apr ’25 | €3.92 | €5.80 +48.0% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Mar ’25 | €3.45 | €5.80 +68.4% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Feb ’25 | €3.81 | €5.80 +52.2% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Jan ’25 | €3.57 | €5.80 +62.7% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Dec ’24 | €2.90 | €5.80 +100.0% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Nov ’24 | €2.58 | €5.80 +124.8% | 33.3% | €8.00 | €3.30 | €3.72 | 3 |
| Oct ’24 | €2.62 | €5.80 +121.8% | 33.3% | €8.00 | €3.30 | €4.71 | 3 |
| Sep ’24 | €2.97 | €6.03 +103.1% | 27.1% | €8.00 | €4.00 | €5.18 | 3 |
| Aug ’24 | €3.18 | €6.37 +100.5% | 20.5% | €8.00 | €4.80 | €6.02 | 3 |
| Jul ’24 | €3.02 | €6.37 +110.8% | 20.5% | €8.00 | €4.80 | €6.19 | 3 |
| Jun ’24 | €2.99 | €6.37 +112.9% | 20.5% | €8.00 | €4.80 | €6.50 | 3 |
| May ’24 | €4.07 | €6.37 +56.6% | 20.5% | €8.00 | €4.80 | €4.33 | 3 |
| Apr ’24 | €3.96 | €6.37 +60.8% | 20.5% | €8.00 | €4.80 | €3.92 | 3 |
| Mar ’24 | €3.95 | €6.37 +61.2% | 20.5% | €8.00 | €4.80 | €3.45 | 3 |
| Feb ’24 | €4.49 | €6.70 +49.4% | 25.9% | €9.00 | €4.80 | €3.81 | 3 |
| Jan ’24 | €3.61 | €6.43 +78.2% | 31.8% | €9.00 | €4.00 | €3.57 | 3 |
| Dec ’23 | €3.17 | €6.43 +103.3% | 31.8% | €9.00 | €4.00 | €2.90 | 3 |
| Nov ’23 | €2.47 | €7.23 +193.4% | 27.1% | €9.00 | €4.50 | €2.58 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Sensus Healthcare
US$143.9m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$8.25
7D
4.4%
1Y
263.8%
Shandong Weigao Group Medical Polymer
HK$20.2b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.9%
1Y
-37.7%
LNA Santé
€240.3m
Engages in the management and operation of health establishments.
2N3
€23.00
7D
1.5%
1Y
17.7%